Cannell & Co’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $371K | Sell |
3,674
-871
| -19% | -$84.1K | 0.01% | 223 |
|
|
2023
Q3 | $463K | Buy |
4,545
+21
| +0.5% | +$2.13K | 0.02% | 203 |
|
|
2023
Q2 | $457K | Sell |
4,524
-162
| -3% | -$16.2K | 0.02% | 206 |
|
|
2023
Q1 | $431K | Sell |
4,686
-105
| -2% | -$9.17K | 0.02% | 215 |
|
|
2022
Q4 | $435K | Buy |
4,791
+85
| +2% | +$7.16K | 0.02% | 211 |
|
|
2022
Q3 | $358K | Sell |
4,706
-390
| -8% | -$32.3K | 0.01% | 218 |
|
|
2022
Q2 | $431K | Sell |
5,096
-400
| -7% | -$35.1K | 0.02% | 212 |
|
|
2022
Q1 | $482K | Hold |
5,496
| – | – | 0.01% | 227 |
|
|
2021
Q4 | $481K | Sell |
5,496
-1,000
| -15% | -$83K | 0.01% | 229 |
|
|
2021
Q3 | $531K | Sell |
6,496
-2,131
| -25% | -$192K | 0.02% | 214 |
|
|
2021
Q2 | $787K | Sell |
8,627
-1,200
| -12% | -$107K | 0.02% | 197 |
|
|
2021
Q1 | $840K | Sell |
9,827
-1,150
| -10% | -$103K | 0.03% | 191 |
|
|
2020
Q4 | $1.04M | Hold |
10,977
| – | – | 0.03% | 166 |
|
|
2020
Q3 | $955K | Sell |
10,977
-1,200
| -10% | -$104K | 0.04% | 155 |
|
|
2020
Q2 | $1.06M | Hold |
12,177
| – | – | 0.04% | 142 |
|
|
2020
Q1 | $1M | Sell |
12,177
-9,875
| -45% | -$881K | 0.05% | 142 |
|
|
2019
Q4 | $2.09M | Buy |
22,052
+1,025
| +5% | +$92K | 0.07% | 134 |
|
|
2019
Q3 | $1.83M | Buy |
21,027
+935
| +5% | +$84K | 0.07% | 133 |
|
|
2019
Q2 | $1.83M | Sell |
20,092
-2,621
| -12% | -$222K | 0.07% | 130 |
|
|
2019
Q1 | $1.96M | Buy |
22,713
+219
| +1% | +$17.6K | 0.08% | 127 |
|
|
2018
Q4 | $1.73M | Hold |
22,494
| – | – | 0.08% | 131 |
|
|
2018
Q3 | $1.74M | Sell |
22,494
-753
| -3% | -$55.7K | 0.06% | 142 |
|
|
2018
Q2 | $1.57M | Buy |
23,247
+111
| +0.5% | +$7.66K | 0.06% | 141 |
|
|
2018
Q1 | $1.68M | Sell |
23,136
-1,524
| -6% | -$116K | 0.06% | 141 |
|
|
2017
Q4 | $1.85M | Hold |
24,660
| – | – | 0.06% | 138 |
|
|
2017
Q3 | $1.9M | Hold |
24,660
| – | – | 0.07% | 134 |
|
|
2017
Q2 | $1.84M | Buy |
24,660
+669
| +3% | +$47.4K | 0.06% | 136 |
|
|
2017
Q1 | $1.6M | Sell |
23,991
-1,450
| -6% | -$96.6K | 0.06% | 152 |
|
|
2016
Q4 | $1.66M | Sell |
25,441
-503
| -2% | -$32.6K | 0.06% | 143 |
|
|
2016
Q3 | $1.84M | Sell |
25,944
-1,506
| -5% | -$110K | 0.07% | 144 |
|
|
2016
Q2 | $2.03M | Hold |
27,450
| – | – | 0.07% | 140 |
|
|
2016
Q1 | $1.78M | Sell |
27,450
-670
| -2% | -$45.6K | 0.06% | 142 |
|
|
2015
Q4 | $2.17M | Hold |
28,120
| – | – | 0.07% | 137 |
|
|
2015
Q3 | $2.32M | Buy |
28,120
+7,868
| +39% | +$700K | 0.08% | 139 |
|
|
2015
Q2 | $1.78M | Sell |
20,252
-502
| -2% | -$46.1K | 0.05% | 151 |
|
|
2015
Q1 | $1.83M | Sell |
20,754
-1,060
| -5% | -$94K | 0.05% | 149 |
|
|
2014
Q4 | $1.81M | Sell |
21,814
-391
| -2% | -$32.4K | 0.05% | 149 |
|
|
2014
Q3 | $1.94M | Sell |
22,205
-937
| -4% | -$75.8K | 0.06% | 147 |
|
|
2014
Q2 | $1.88M | Sell |
23,142
-16,541
| -42% | -$1.3M | 0.06% | 150 |
|
|
2014
Q1 | $3.02M | Buy |
+39,683
| New | +$2.89M | 0.1% | 129 |
|
Other funds holding NVS
Cannell & Co's NVS Position: Q4 2023 in Review
Cannell & Co reduced its Novartis (NVS) stake by 19% in Q4 2023, selling an estimated $84.1K and leaving 3,674 shares worth $371K. The position accounts for 0.01% of the portfolio, ranked #223.
Cannell & Co first reported a position in NVS in Q1 2014 and has held it in 40 quarters since. The position peaked at $3.02M in Q1 2014. 1,272 funds tracked by Wall St. Rank hold NVS as of Q4 2023.
- Cannell & Co held 3,674 shares of Novartis worth $371K as of Q4 2023.
- Cannell & Co sold 871 Novartis shares in Q4 2023, an estimated $84.1K.
- Novartis made up 0.01% of Cannell & Co's portfolio in Q4 2023, its #223 holding.
- Cannell & Co first reported a position in Novartis in Q1 2014 and has held it in 40 quarters since.
- Cannell & Co's Novartis position peaked at $3.02M in Q1 2014.
- 1,272 funds tracked by Wall St. Rank held Novartis as of Q4 2023.
Based on Cannell & Co's 13F filing for Q4 2023, filed 5 Feb 2024.